MEDIA
We are open for communication and dialogue.
Our Company is one of the first on the Russian venture investment market. For more than 8 years, Maxwell Biotech has been working in the field of biotechnology and pharmaceuticals and has a unique team capable of implementing highly advanced and complicated projects. During these years we have accumulated great experience in managing venture projects, developing medical drugs, conducting clinical trials and in successful international partnership.
Our experts are prepared to share their vision of venture investment prospects, to speak about the medications we develop, relevant trends, assessing the current progress in the industry and sharing our successful experience in addressing specific issues in real-life cases.
In the attached files you can find the profile of Maxwell Biotech Group’s speaker, detailed information about portfolio companies and medical drugs under development.
Maxwell Biotech Group, +7 (495) 726-52-53, bakrenko@ammaxwell.ru
-
Read more + 29.09.2016 By maxwell.admin in News
Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma
-
Read more + 28.06.2016 By maxwell.admin in News
NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the treatment of neuropathic pain
-
Read more + 01.06.2016 By maxwell.admin in News
Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
-
Read more + 28.03.2016 By maxwell.admin in News
Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection
-
Read more + 02.04.2014 By maxwell.admin in News
Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Initiation of a Pilot Clinical Trial Of Myrcludex B In Patients With HDV
-
Read more + 07.03.2014 By maxwell.admin in News
Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Completes Enrollment of Phase IIa clinical trial of Myrcludex B, for HBV
-
Read more + 14.02.2014 By maxwell.admin in News
Maxwell Biotech Venture Fund’s Portfolio Company Infectex Acquires Exclusive Rights to Qurient’s Tuberculosis Drug Q203
-
Read more + 26.11.2013 By maxwell.admin in News
OncoMax research received “FIRST PRIZE” award at EMUC- 2013
-
Read more + 11.11.2013 By maxwell.admin in News
OncoMax, MetaMax, Osteros Biomedica will take part in the XVII Russian Cancer Congress
-
Read more + 23.10.2013 By maxwell.admin in News
Oncomax and Metamax are Prix Galien Russia 2013 Nominees for “Best Research in Russia”
-
Read more + 29.04.2016 By maxwell.admin in Publications
Journal of Hepatology: Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients
-
Read more + By maxwell.admin in Publications
Journal of Hepatology: Myrcludex B: a first-in-human clinical study with a first-in-class hepatitis B and hepatitis D virus entry inhibitor
-
Read more + 25.12.2013 By maxwell.admin in Publications
Maxwell Biotech Portfolio in “In the Morning” on NTV
-
Read more + 18.11.2013 By maxwell.admin in Publications
StLase modular laser system and other technological innovations at the exhibition of the Second Moscow International Forum “Open Innovations”
-
Read more + 17.10.2013 By maxwell.admin in Publications
“Vesti. Innovation Center” dated October 17, 2013
-
Read more + 18.01.2013 By maxwell.admin in Publications
Photonics appears in Technology Update for the 2nd time in a row
-
Read more + 17.12.2012 By maxwell.admin in Publications
Hepatera is confident that Myrcludex B can be helpful in defeating chronic hepatitis B
-
Read more + 05.12.2012 By maxwell.admin in Publications
Open Innovation Expo 2012 participant Photonics appears in Technology Update
-
Read more + 20.11.2012 By maxwell.admin in Publications
CardioNova appears in “In the Morning” on NTV
-
Read more + 23.10.2012 By maxwell.admin in Publications
stLase appears in NTV programm “In the Morning”